Production (Stage)
Fresh Tracks Therapeutics, Inc.
FRTX
OTC PK
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 8.01M | 10.06M | 2.60M | 6.86M | 6.94M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.01M | 10.06M | 2.60M | 6.86M | 6.94M |
| Cost of Revenue | 3.18M | 5.78M | 8.71M | 9.97M | 14.04M |
| Gross Profit | 4.82M | 4.28M | -6.11M | -3.11M | -7.10M |
| SG&A Expenses | 11.18M | 13.58M | 11.26M | 13.36M | 14.43M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.37M | 19.36M | 19.97M | 23.33M | 28.48M |
| Operating Income | -6.36M | -9.30M | -17.37M | -16.47M | -21.53M |
| Income Before Tax | -5.69M | -8.98M | -17.11M | -15.97M | -21.10M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.69 | -8.98 | -17.11 | -15.97 | -21.10 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -197.00K | -197.00K | -- | -- | -- |
| Net Income | -5.89M | -9.18M | -17.11M | -15.97M | -21.10M |
| EBIT | -6.36M | -9.30M | -17.37M | -16.47M | -21.53M |
| EBITDA | -6.32M | -9.26M | -17.34M | -16.44M | -21.50M |
| EPS Basic | -1.41 | -2.70 | -5.10 | -5.14 | -7.55 |
| Normalized Basic EPS | -0.89 | -1.70 | -3.19 | -3.21 | -4.72 |
| EPS Diluted | -1.41 | -2.70 | -5.10 | -5.14 | -7.55 |
| Normalized Diluted EPS | -0.89 | -1.70 | -3.19 | -3.21 | -4.72 |
| Average Basic Shares Outstanding | 21.55M | 18.59M | 15.58M | 12.33M | 11.23M |
| Average Diluted Shares Outstanding | 21.55M | 18.59M | 15.58M | 12.33M | 11.23M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |